[{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oil","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"8","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Idarubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"8","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gadoterate","moa":"Gadolinium (MRI contrast)","graph1":"Nephrology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Gadobutrol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gadobutrol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase II","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Undisclosed","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Nephrology","graph2":"Phase I","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Bracco"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Undisclosed","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Undisclosed","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Oncology","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase II","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Oncology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Gadoterate Meglumine","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Gadoterate Meglumine","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Nephrology","graph2":"Phase I","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Gadoterate Meglumine","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase III","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Gadoterate Meglumine","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Oncology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Gadoterate Meglumine","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Oncology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Gadoterate Meglumine","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Oncology","graph2":"Phase I","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"6","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Gadoversetamide","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Iobitridol","moa":"Iodine","graph1":"Oncology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Iobitridol","moa":"iodine-containing contrast media","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Iobitridol","moa":"iodine-containing contrast media","graph1":"Endocrinology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iodixanol","moa":"iodine-containing contrast media","graph1":"Oncology","graph2":"Phase I","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"6","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iodized Oil","moa":"iodine-containing contrast media","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"6","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Iodized Oil","moa":"iodine-containing contrast media","graph1":"Oncology","graph2":"Phase II","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"8","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"Ioxaglic Acid","moa":"iodine-containing contrast media","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"Bayer AG | Bracco | GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gadolinium Ethoxybenzyl Dtpa","moa":"MRI contrast","graph1":"Neurology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Bayer AG | Bracco | GE Healthcare","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Bayer AG | Bracco | GE Healthcare"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gadolinium","moa":"Ribonucleoside-diphosphate reductase RR1 | Thioredoxin reductase 1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ethynodiol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"GUERBET","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ethynodiol","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Catheter","sponsorNew":"GUERBET \/ GUERBET","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ GUERBET"},{"orgOrder":0,"company":"GUERBET","sponsor":"NUCLIDIUM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"NuriPro","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ NUCLIDIUM","highestDevelopmentStatusID":"4","companyTruncated":"GUERBET \/ NUCLIDIUM"},{"orgOrder":0,"company":"GUERBET","sponsor":"Dipan Shah","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Gadoterate Meglumine","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ Dipan Shah","highestDevelopmentStatusID":"1","companyTruncated":"GUERBET \/ Dipan Shah"}]
Find Clinical Drug Pipeline Developments & Deals by GUERBET
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
